Based in Vancouver, British Columbia, Canada, InMed's strategic focus is the development of prescription, cannabinoid-based pharmaceutical products. We commenced our current activities in May, 2014, upon the acquisition of a privately-held British Columbia based biopharmaceutical company focused on the drug discovery and development of cannabinoid compounds.

In the ensuing years, our leadership team has taken numerous steps and corporate actions to de-risk and solidify our capital structure, fortify our cash position and liquidity, assemble a world class leadership team with a successful track record in drug development, strengthen our potentially game-changing bioinformatics and biosynthesis platform technologies, and deploy and advance our cannabinoid-based pipeline of drug candidates across a spectrum of diseases with high unmet medical needs.

Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any others.